Scarica l'app Stockscreener
1.24
0.80%
-0.01
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché MBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.25
Aprire:
$1.25
Volume 24 ore:
39,492
Relative Volume:
0.10
Capitalizzazione di mercato:
$5.73M
Reddito:
-
Utile/perdita netta:
$-23.42M
Rapporto P/E:
-0.0159
EPS:
-78
Flusso di cassa netto:
$-16.67M
1 W Prestazione:
-5.34%
1M Prestazione:
+9.25%
6M Prestazione:
-87.11%
1 anno Prestazione:
-84.00%
Intervallo 1D:
$1.21
$1.26
Intervallo di 1 settimana:
$1.21
$1.31
Portata 52W:
$1.01
$65.00
Mustang Bio Inc Stock (MBIO) Company Profile
Nome
Mustang Bio Inc
Settore
Industria
Telefono
(781) 652-4500
Indirizzo
377 PLANTATION STREET, WORCESTER, NY
Confronta MBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
1.24 | 5.73M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2020-10-02 | Iniziato | B. Riley FBR | Buy |
| 2019-11-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-08-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Mustang Bio Inc Borsa (MBIO) Ultime notizie
ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress - insights.citeline.com
Pre-market Movers: LIMN, KRON, HSDT, CBUS... - RTTNews
Why MongoDB Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
CAR T Cell Therapy Market Projected to Witness Massive Growth - openPR.com
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Mustang Bio Reports Improved Financials Amid Strategic Adjustments - TipRanks
Mustang Bio (NASDAQ:MBIO) Rating Increased to Hold at Wall Street Zen - Defense World
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Asia-Pacific Personalized Cell Therapy Market Report - openPR.com
Arvinas (NASDAQ:ARVN) and Mustang Bio (NASDAQ:MBIO) Financial Contrast - Defense World
Geode Capital Management LLC Purchases 38,951 Shares of Mustang Bio, Inc. (NASDAQ:MBIO) - Defense World
Cell Therapy Market Growth Set to Surge Significantly during 2025 – 2032 - newstrail.com
Closing Bell Recap: Mustang Bio Inc (MBIO) Ends at 1.22, Reflecting a -1.61 Downturn - DWinneX
Mustang Bio stock plunges to 52-week low of $2.6 amid sharp decline - MSN
Mustang Bio stock plunges to 52-week low of $1.12 - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.12 By Investing.com - Investing.com South Africa
Financial Analysis: Bio-Key International Inc (BKYI)’s Ratios Unveil Key Insights - DWinneX
Cell Therapy Market Future Path and Key Opportunities 2025 – 2032 - newstrail.com
Mustang Bio (MBIO) Sells Facility to AbbVie for $1 Million - GuruFocus
Mustang Bio Inc: Rising -98.18% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Mustang Bio (MBIO) Regains Nasdaq Compliance - GuruFocus
Now Is The Time To Build A Position In Mustang Bio Inc (NASDAQ:MBIO) - Marketing Sentinel
What to expect from MBIO’s earnings report this quarter? - uspostnews.com
Mustang Bio stock hits 52-week low at $1.20 amid sharp decline - Investing.com Canada
Mustang Bio stock hits 52-week low at $1.20 amid sharp decline By Investing.com - Investing.com South Africa
Mustang Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mustang Bio Inc. (MBIO) reports earnings - Quartz
MUSTANG BIO, INC. SEC 10-K Report - TradingView
Mustang Bio stock plunges to 52-week low of $1.35 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.35 - Investing.com India
Fortress Biotech partners with Partex for AI-driven drug discovery - Investing.com
Car T Cell Therapy Market Demand, Statistics, Future Growth and Outlook 2025-2032 | Mustang Bio, Fate Therapeutics - openPR
Mustang Bio stock plunges to 52-week low of $1.43 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.43 - Investing.com India
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Petri Dish: Biotech leaves Worcester; Novo Nordisk, Eli Lilly partnerships - The Business Journals
Mustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy Advancements - Nasdaq
Mustang Bio meets Nasdaq’s equity listing requirements By Investing.com - Investing.com Canada
Mustang Bio meets Nasdaq’s equity listing requirements - Investing.com India
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - The Manila Times
Mustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing Requirements - Nasdaq
Mustang Bio Overcomes Delisting Threat: What This Nasdaq Compliance Means for Investors - StockTitan
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
BRIEF—Mustang Bio sells assets; focuses on MB-109, MB-108 and MB-101 - The Pharma Letter
Mustang Bio Inc Azioni (MBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):